Rules for biocatalyst and reaction engineering to implement effective, NAD(P)H-dependent, whole cell bioreductions  by Kratzer, Regina et al.
Biotechnology Advances 33 (2015) 1641–1652
Contents lists available at ScienceDirect
Biotechnology Advances
j ourna l homepage: www.e lsev ie r .com/ locate /b iotechadvResearch review paperRules for biocatalyst and reaction engineering to implement effective,
NAD(P)H-dependent, whole cell bioreductionsRegina Kratzer a,⁎, John M. Woodley b, Bernd Nidetzky a,⁎
a Institute of Biotechnology and Biochemical Engineering, Graz University of Technology, Petersgasse 12/I, 8010 Graz, Austria
b CAPEC-PROCESS Research Center, Department of Chemical and Biochemical Engineering, Technical University of Denmark, Søltofts Plads Building 229, 2800 Kgs. Lyngby, Denmark⁎ Corresponding authors.
E-mail addresses: regina.kratzer@tugraz.at (R. Kratzer
http://dx.doi.org/10.1016/j.biotechadv.2015.08.006
0734-9750/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 19 May 2015
Received in revised form 21 August 2015
Accepted 31 August 2015
Available online 3 September 2015
Keywords:
Chiral alcohol
Decision tree for bioreduction development
Design of Escherichia coliwhole cell catalysts
Limitations of whole cell reductions
Cost analysis
Scale-upAccess to chiral alcohols of high optical purity is today frequently provided by the enzymatic reduction of
precursor ketones. However, bioreductions are complicated by the need for reducing equivalents in the form
of NAD(P)H. The high price andmolecular weight of NAD(P)H necessitate in situ recycling of catalytic quantities,
which is mostly accomplished by enzymatic oxidation of a cheap co-substrate. The coupled oxidoreduction can
be either performed by free enzymes in solution or by whole cells. Reductase selection, the decision between
cell-free and whole cell reduction system, coenzyme recycling mode and reaction conditions represent design
options that strongly affect bioreduction efﬁciency. In this paper, each option was critically scrutinized and
decision rules formulated based on well-described literature examples. The development chain was visualized
as a decision-tree that can be used to identify the most promising route towards the production of a speciﬁc
chiral alcohol. General methods, applications and bottlenecks in the set-up are presented and key experiments
required to “test” for decision-making attributes are deﬁned. The reduction of o-chloroacetophenone to
(S)-1-(2-chlorophenyl)ethanol was used as one example to demonstrate all the development steps. Detailed
analysis of reported large scale bioreductions identiﬁed product isolation as amajor bottleneck in process design.
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Numbers one, two, three and nine out of the 10 top-selling drugs
in history are non-peptidic, enantiopure molecules (data from October
2013; Nixon, 2013) and chiral compounds will, as reckoned by analysts,
still have a prominent position on blockbuster drug lists by 2020
(Brown, 2014). Single-enantiomer pharmaceuticals are typicallyFig. 1. General scheme of bioreductions catalyzed by free enzymes or whole cells (gray
catalyzed by recombinant E. coli based on CtXR and CbFDH (the dashed oval line depicts cell per
(B). Schemeof themultiphasic o-chloroacetophenonebioreduction at 0.5-L scale. The reactionw
thebiomass, blue drops show thehexanephase extracting o-chloroacetophenone and (S)-1-(2-
that was obtained per batch (20 g) and that was further analyzed by chiral HPLC (C).administered in optical purities of 98% e.e. and above (Pollard and
Woodley, 2007). Such enantiomeric purities are best obtained from
enzyme-catalyzed reactions. Hence, there is a strongdrive to implement
biocatalytic steps into synthetic routes towards many pharmaceutical
products (Wohlgemuth, 2007). Enantiopurity is generally obtained ei-
ther by synthesizing speciﬁcally one enantiomer or resolving a
racemic mixture. The quest for synthetic efﬁciency naturally favorsoval indicates the cell envelope) (A). Whole cell reduction of o-chloroacetophenone
meabilization, the blue hexagons illustrate isss and ispr by a water immiscible co-solvent).
as performed in a stirred tank reactorwith pHand temperature control (gray points depict
chlorophenyl)ethanol). The three tubes show the extracted (S)-1-(2-chlorophenyl)ethanol
Fig. 2.Decision tree for the set-up of bioreductions. Rounded rectangles represent decision
rules, blue squares show process solutions, inefﬁcient branches are terminated by blue
circles. (Process options for cell-free bioreduction systems are not further developed.)
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chiral resolution of a racemic mixture (Federsel, 2006; Straathof et al.,
2002; Trost, 1991). The most often exploited enantioselective
biotransformation in industry is the reduction of a ketone precursor
into an optically pure alcohol (Pollard and Woodley, 2007). Enzymes
catalyzing carbonyl reduction are mostly dependent on the reduced
form of the coenzyme NAD(P). However, stoichiometric addition of
NAD(P)H(N700 g/mol) is neither technically nor economically feasible,
thus requiring the in situ recycling of catalytic quantities. Coenzyme
regeneration is generally accomplished by the enzymatic oxidation of
a cheap co-substrate. The coupled oxidoreduction is either performed
by cell-free oxidoreductases or by whole cell systems (Fig. 1A). A pre-
requisite for both systems is the selection of an enantioselective reduc-
tase. Oxidoreductase properties, the decision between cell-free and
whole cell reduction system and reaction design complexity affect the
bioreduction efﬁciency. A key task therefore in implementing a new
bioreduction is the selection of the most efﬁcient strategy among a
multitude of possibilities.
1.1. Scope of the review
It is the aim of the present review to outline the design of whole cell
bioreductions and critically scrutinize decisions along the development
chain. We thereby introduce a graphical tool that helps to identify a
strategy for the most effective production of a speciﬁc alcohol (Fig. 2).
The depicted decision tree consists of seven nodes covering screening
for active microbes, reductase selection, the decision between a cell-
free and whole cell reduction system, coenzyme recycling alternatives
and process options. Decisions are guided by the properties of the
substrate and the requirement for optical purity and amount of product
(Fig. 2). Decision rules are based on a small number of biocatalytic
reactions that are thoroughly described in the scientiﬁc literature.
Bottlenecks along the development cycle of bioprocesses are presented
in detail. Finally scale-up aspects that are speciﬁc for whole cell
bioreductions are discussed. Clearly, coverage of all scientiﬁc literature
in the respective area is beyond the scope of this manuscript.
2. Development chain of bioreductions
2.1. Enzyme sources
The decision to use biocatalysis in synthetic chemistry is mainly
justiﬁed by the superior enantioselectivity enzymes provide in compar-
ison to chemo-catalysts. Enantioselectivity is hence the key criterion for
enzyme selection in the production of chiral synthons (Kita et al., 1999;
Pollard and Woodley, 2007). The wide abundance of reductases in
nature renders screening of strain libraries or literature searching for
the best ﬁtting candidate oftentimes more cost and time effective than
enzyme engineering.
2.1.1. Screening of microbial hosts
The criterion for strain selection is primarily the whole cell activity
towards the target substrate (Fig. 2, node 1). An enantiopure product
proves the existence of one or more enantioselective reductases. In
this case, the native strain might be directly applied in the production
of a limited amount of product (Fig. 2) in particular in the early stages
of process development (Pollard and Woodley, 2007). An active strain
that shows low or no enantioselectivity harbors either enzymes that
are unselective, enzymes with opposite enantioselectivities or both.
The so-called “reductase background” of native hosts is strongly strain
and substrate dependent. o-Chloroacetophenone, as an example,
is barely utilized as a substrate by abundant reductases and is hence
converted into the enantiopure alcohol by reductase-rich microor-
ganisms like Pichia stipitis, Candida tenuis or Candida pseudotropicalis
(Gruber et al., 2013; Xie et al., 2006). The ability to reduce, for instance,
α-keto esters is common among reductases. Bioreductions of an ethylbenzoylformate by C. tenuis and P. stipitis cells resulted in low ee values
of 65 and 80%, respectively (Gruber et al., 2013). Previous efforts to
overcome contrasting reductase activities included adjusting the sub-
strate concentration, use of additives to selectively inhibit one or more
competing enzymes and genetic knockout approaches (Kaluzna et al.,
2004). In practice, these strategies are often only partially successful
and the more straightforward strategy in these cases is to investigate
the enzyme(s) in its isolated form. Stereoselectivities of whole cells
or isolated enzymes are analyzed by chiral chromatography of
corresponding reduction products (Fig. 2, node 2, node 3).
2.2. Catalyst level
Stereoselective enzymes can generally be used in cell-free form or
as whole cell catalysts. The cell envelope shields enzymes from the
reaction medium and thereby increases enzyme stability but may also
decrease reaction rate. The utilization of free reductases, on the con-
trary, minimizes mass transfer limitations but exposes the enzyme
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cells and free enzymes show opposite characteristics with respect to
catalyst activity and lifetime. The way in which the total turnover of
the catalyst (i.e. the product of catalyst activity and lifetime) is affected
when whole cells are used instead of free enzymes, is case speciﬁc.
The cell envelope constitutes a barrier to the surrounding medium
and therefore, transfer of hydrophilic compounds in and out of the cell
requires speciﬁc transporter systems (Daugelavičius et al., 2000; Kell
et al., 2015). Consequently, bioreductions of hydrophilic substrates
that are harmless to free enzymes might yield higher product concen-
trations when oxidoreductases are directly applied as free enzymes.
Mädje et al. (2012) have previously reported on a two-fold higher
xylitol concentrationwhen free enzymeswere used instead of recombi-
nant Escherichia coli in the bioreduction of xylose. Expression of a
transporter protein is a further option. The co-expression of a transport-
er protein facilitated glucose uptake by an E. coliwhole cell catalyst and
increased mannitol production N10-fold (Kaup et al., 2004). Hydropho-
bic molecules enter the cell by slow diffusion through the lipopolysac-
charide cell wall and subsequent partition into the cell membrane
(Daugelavičius et al., 2000). Whole cells turned out as the catalyst of
choice in cases of fast enzyme deactivation by hydrophobic substrates
and products (Schmölzer et al., 2012). The cell envelope provides on
the one hand protection of intracellular enzymes while on the other
hand it is permeable enough for hydrophobic substrates to keep the
reaction going. The bioreduction of ethyl 4-chlorobutanoate to ethyl
(S)-4-chloro-3-hydroxybutyrate is one route towards the chiral side
chain of the blood cholesterol lowering Atorvastatin, the top selling
drug of all time (Nixon, 2013; Thayer, 2006). Ethyl (S)-4-chloro-3-
hydroxybutyrate synthesis has been thoroughly optimized and product
concentrations of 0.8 and 2.6 Mwere reported for reductions using free
enzymes andwhole cells, respectively (Kizaki et al., 2001; Shimizu et al.,
1990). The lowhydrophobicity of the substrate (logP 0.23; CAS database
https://sciﬁnder.cas.org) permits economic production using either free
enzymes or whole cells (note the additional complication of substrate
hydrolysis). Likewise, efﬁcient production of L-tert-leucine by transam-
inases has been reported using free enzymes andwhole cells (Tufvesson
et al., 2011). These examples indicate that the hydrophobicity of a
substrate can be used to choose the preferable form of the biocatalyst,
i.e. free enzyme orwhole cells. These examples suggest that hydrophilic
substrates (logP ˂ 0) are best converted by free enzymes and hydropho-
bic substrates (logP N 1) by whole cells. Additionally, substrates that
show logP values between approximately 0 and 1 are efﬁciently
converted by both whole cells and free enzymes. We used substrate
logP ˂ 1 as criteria for a cell-free bioreduction system (Fig. 2, node 4;
the possibility to use whole cells or free enzymes for substrates with
logP values between 0 and 1 is not indicated).
2.2.1. Native hosts
Both recombinant and native microorganisms have been previously
employed as bioreduction systems. The application of native strains
shortens the process development time by avoiding multiple steps of
strain construction (Pollard and Woodley, 2007). However, products
obtained from bioreductions using native strains most often show
lower enantiopurity and yields, compared to reductions catalyzed by
recombinant strains of E. coli (Gruber et al., 2013; Yasohara et al.,
1999; Kizaki et al., 2001). Usability of the native strain, either employed
as cell-free or whole cell systems, depends therefore on the actual
requirement for product purity and amount (Fig. 2, node 5).
2.2.2. Recombinant E. coli
E. coli is easy to manipulate and has been shown to accumulate
recombinant protein to a level of up to 55% of the soluble cell protein
(Tishkov and Popov, 2006) or, as inclusion bodies, N50% of the total
cellular protein (Baneyx and Mujacic, 2004). Recombinant E. coli is
hence most often used as a “designer-bug” in whole cell bioreductions
(Goldberg et al., 2007; Gröger et al., 2006; Kataoka et al., 2003).NAD(P)H-dependent carbonyl reductases transfer a hydride from the
coenzyme to the carbonyl and protonate the nascent alcoholate. The
reaction is hence consuming a hydride from NAD(P)H and a proton
from the aqueous phase. A highly expressed reductase is, however,
not optimally supplied with reduced coenzyme by the E. coli inherent
metabolism (Kataoka et al., 1997). The expression of a second
oxidoreductase to recycle NAD(P)H (Fig. 1A) is especially important
under harsh reaction conditions that lead to elevated maintenance
metabolism (Blank et al., 2008). Maximum use of the cell capacity
is made when intracellular reductase and dehydrogenase activities
are balanced against each other (Mädje et al., 2012).The most often
exploited dehydrogenases in order to recycle NAD(P)H are formate
and glucose dehydrogenases (FDHs, GDHs). Most FDHs are NAD+-
speciﬁc; NADPH recycling by formate oxidation requires the applica-
tion of a mutant FDH (Tishkov and Popov, 2006). In contrast, glucose
dehydrogenases display dual speciﬁcities for NAD+ and NADP+.
Both enzymes catalyze an irreversible reaction and thereby drive
coupled reactions to completion. FDHs oxidize formate to carbon
dioxide in a pH-neutral reaction. The overall oxidoreduction is
consuming a proton as shown in Fig. 1B (Neuhauser et al., 1998).
GDHs abstract a hydride and a proton from glucose to form
NAD(P)H, H+ and glucono-δ-lactone. The overall reaction, when
coupled to a carbonyl reductase, is pH neutral. The co-product
glucono-δ-lactone is spontaneously hydrolysed leading to gluconate
(Tishkov and Popov, 2006). FDHs display speciﬁc activities of 4 to
10 U/mg (EC 1.2.1.2; www.brenda-enzymes.org) while glucose dehy-
drogenases are among the most active dehydrogenases with activities
of approximately 300 to 500 U/mg (EC 1.1.1.47; www.brenda-
enzymes.org). So why not use GDH in all cases? NAD(P)H recycling by
FDH, despite the enzyme's low activity, displays three advantages.
First, the molecular weight of formate (HCOONa) is 2.6-fold lower
than that of glucose. Use of formate is hence more atom and cost eco-
nomic. Secondly, the product of the reaction, carbon dioxide, is innocu-
ous and evaporates from the reaction. Third, the required pH-titration
by addition of formic acid provides an elegant way of pH-titration and
co-substrate supply in a single step (Neuhauser et al., 1998). The reac-
tion mixture is hence devoid of large amounts of co-substrate or co-
product throughout reaction and product isolation when FDH is used
for coenzyme recycling. Therefore, reductases with relatively low spe-
ciﬁc activities are generally coupled to FDHs in order to beneﬁt from
the process advantages that FDHs provide (Mädje et al., 2012). Indeed,
the high speciﬁc activities of GDHs are hardly exploited when coupled
to reductases with low speciﬁc activities and are hence co-expressed
with highly active reductases to enable a fast intracellular oxidoreduction
(Gröger et al., 2006; Kizaki et al., 2001). The decision between FDH
and GDH as coenzyme recycling enzyme is therefore best based de-
cided on the speciﬁc reductase activity. Reductases with speciﬁc ac-
tivities of less than approximately 15 U/mg are best co-expressed
with FDHs and reductases with higher speciﬁc activities coupled to
GDHs (Fig. 2, node 6).
2.2.3. Limitations of whole cell catalysts
2.2.3.1. Mass transfer over cell wall and membrane. Whole cells usually
show substantial activity losses when compared to their corresponding
cell-free extracts (Alphand et al., 2003; Gruber et al., 2013; Rundbäck
et al., 2012). Gruber et al. reportedmaximally 7% of the cell-free activity
when recombinant E. coli, Saccharomyces cerevisiae and native C. tenuis
cells were used for the reduction of o-chloroacetophenone (Fig. 1B).
The loss of more than 90% activity is mainly ascribed to mass transfer
limitations over the cell wall leading to a low intracellular concentra-
tion of (co)substrate. Effective substrate and co-substrate supply
in bioreductions, as indicated in Fig. 1B, therefore require cell perme-
ability to hydrophobic substrates and products, as well as hydrophil-
ic co-substrates and co-products. Lipid bilayers are permeable to
hydrophobic molecules although diffusion from the media into the
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Charged or hydrophilic molecules, on the contrary, can only cross
using porins, which are narrow channels for ions and small hydrophilic
nutrients (Daugelavičius et al., 2000). Formate and glucose, the two
most often used co-substrates in bioreductions based on E. coli, are
taken up by native transporter systems of the host (Sawers, 2005). Glu-
cose uptake in E. coli involves coupled transport and phosphorylation.
The resulting glucose 6-phosphate is, however, not a substrate of
GDH. An efﬁcient glucose supply for GDH-catalyzed oxidation in E. coli
therefore requires either engineering of the glucose uptake system or
cell membrane permeabilization. Co-expression of the facilitator-
type transporter GLF (glucose facilitator) from Zymomonas mobilis
has been previously shown to increase the glucose import rate and
decouple phosphorylation (Schroer et al., 2007).E. coli perme-
abilization using the peptide antibiotic polymyxin B sulfate (PMB)
led to an improvement of up to 2-fold bioreduction as reported by
Schmölzer et al. (2012). PMB shows a mainly locally disruptive effect
on cell wall integrity in contrast to cell permeabilization by solvents,
detergents or salts (reviewed by Chen, 2007).
The interaction of PMB with bacterial membranes starts with
binding to the lipopolysaccharide (LPS) outer layer, thereby disturbing
the LPS packing and promoting its own uptake (“self-promoted”
uptake). In a second step, PMB induces the fusion of outer as well as
cellular membranes to form envelope-crossing, ion permeable pores
(Daugelavičius et al., 2000). The disordered LPS layer facilitates faster
cell permeation by hydrophobic molecules while the formed pores
connect the cytosol directly to the cell exterior and enable uptake of
charged or hydrophilic compounds. Cell wall porosity leads also to
diffusional loss of intracellular coenzymes and hence requires addition
of NAD(P)(H) to reaction mixtures (Chen, 2007).
2.2.3.2. Catalyst stability. Hydrophobic compounds generally show
a toxic effect towards microbial cells by partition into cellular mem-
branes. Accumulation of hydrophobicmolecules results in swelling, per-
meabilization and ﬁnally loss of membrane integrity. Cell breakdown is
estimated at membrane concentrations of around 300 to 400 mM of
accumulated molecules. Partition of a hydrophobic compound into
membranes is proportional to (1) its concentration in the aqueous
phase and (2) its membrane-aqueous phase partition coefﬁcient
(De Bont, 1998). A relationship between the partitioning of a compound
between the membrane and water (logPM/W) and its logP value has
been previously reported by Sikkema et al. (1994) (Eq. (1)):
logPM=W ¼ 0:97∙ logP−0:64: ð1Þ
Eq. (1) allows predictions to be made about the toxicity of
hydrophobic compounds based on their logP values. Highly hydro-
phobic molecules with logP values N4 accumulate in membranes
but will not reach a high membrane concentration due to their low
water solubility. In contrast, molecules with logP values between 1
and 4 are more water soluble and still partition into membranes,
thus the achieved membrane concentration will be relatively high
(De Bont, 1998). The question arises whether cells disintegrate
prior to enzyme deactivation or enzymes get deactivated in the cell
due to increasing concentrations of toxic molecules? The results
obtained by Schroer et al. (2007) strongly suggest a deactivation
mechanism with enzyme inactivation prior to cell disintegration.
Two E. coli catalysts based on the same reductase but differing in
the mode of coenzyme recycling were compared in terms of process
stability. The alcohol dehydrogenase from Lactobacillus brevis
(LbADH) was co-expressed with FDH or GDH in E. coli BL21 (DE3).
Coenzyme recycling was either accomplished by formate oxidation
with FDH or by glucose oxidation with GDH. The results indicated a
strong dependence of catalyst stability on the expressed enzymes.
The whole cell catalyst based on GDH showed better performance
in the reduction of acetoacetate. The obtained catalyst half-life was atleast 4-fold higher as compared to whole cell catalysts co-expressing
FDH. GDHs are clearly preferable in continuous bioreduction processes
with recombinant E. coli due to higher process stabilities of GDHs
compared to FDHs (Schroer et al., 2007).
2.3. Reaction level
Eixelsberger et al. (2013) have previously interpreted the efﬁciency
of a bioreduction tomean theﬁnal product concentration in the reaction
mixture. Indeed, as a rule of thumb, product concentrations below
~100 mM generally render bioreduction processes uneconomic.
Especially for whole cell bioreductions that exploit FDH for coenzyme
recycling the use of in situ extraction of substrate and product into a
water-immiscible, secondphase is required to reach product concentra-
tions of ≥100 mM (Schmölzer et al., 2012). On the contrary, product
concentrations of 1 to 1.8 M have been reported for aqueous batch re-
ductionswith E. coli strains co-expressingGDHand a catalytic reductase
(Ema et al., 2008; Gröger et al., 2006; Kataoka et al., 2003). The require-
ment for a second phase in bioreductions that are based on GDHs de-
pends on the process stability of the carbonyl reductase. Therefore,
aqueous batch reductions that yield product concentrations below
100 mM call for the application of a second phase in order to achieve
economic product concentrations (Fig. 2, node 7).
2.3.1.1. In situ substrate supply (isss) and product removal (ispr)
The addition of a water-immiscible phase to a stirred tank reactor
containing the reaction mixture does not seem to be a complex task.
The choice and amount of added solvent is, however, highly empirical
and guidelines for the optimization of biphasic bioreductions are
missing so far. The most important properties of suitable second phases
are their extracting ability for substrate and product and their low
solubility in the aqueous phase itself (logP N 4). The ideal second
phase should provide an optimal substrate concentration in the
aqueous phase and full extraction of the product. Preferred second
phases show moderate to low boiling points (≤100 °C), are nontoxic
and are readily available. The following literature examples for whole
cell reactions might give a starting point for in situ substrate supply
and product removal (isss and ispr) strategies of substrates and
products with similar structures and logP values. Schmölzer et al.
(2012) have reported on a ≥ 10-fold improved yield for an E. coli
whole cell reduction of o-chloroacetophenone by the addition of 20%
v/v n-hexane (Fig. 1B, C). The product concentration of an E. coli
whole cell Baeyer–Villiger oxidation (bicyclo[3.2.0]hept-2-en-6-one to
(−)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one and (−)-(1R,5S)-3-
oxabicyclo[3.3.0]oct-6-en-2-one)was 20-fold increased by the addition
of 100 g/L hydrophobic resin (Optipore L-493; Alphand et al., 2003).
Addition of 50% v/v n-butyl acetate to the E. coli whole cell reduction
of 4-chloro-3-oxobutanoate to the corresponding S-alcohol led to a
high product concentration of 3Mbyprevention of substrate hydrolysis
and biocatalyst protection. These examples indicate that efﬁcient isss
and ispr strategies are highly case-speciﬁc with respect to dissolution
properties of the substrate (and the corresponding product), enzyme
stabilities and enzyme kinetics.
2.4. Diagnostic parameters
Enantiomeric/regiomeric purity, product concentrations and total
turnover numbers (expressed as gram product obtained per gram
biocatalyst) are generally used to assess bioreactions (Pollard and
Woodley, 2007; Straathof et al., 2002). However, the complexity of
whole cell reductions requires yet further criteria to identify possible
limitations. Table 1 lists seven additional parameters that describe
whole cell reductions, but also provide scope for engineering (Gruber
et al., 2013). The intracellular enzyme activity, whole cell activity,
catalyst lifetime and extracellular substrate and product concentrations
are directly measurable (for methods see Section 3). The comparison
Table 1
Diagnostic parameters of whole cell reductions.
Parameter Assessed Experiment
Stereoselectivity Directly Chiral HPLC, GC (see also Section 3.3)
Intracellular enzyme activity (activities) Directly Photometric measurement of NAD(P)(H) depletion (formation) in cell-free
extracts (3.4)
Whole cell activity Directly Initial rates of whole cell reductions (3.6.1)
Activity loss (mass transfer limitation over cell wall) Indirectly Comparison of intracellular enzyme and whole cell activities (3.6.1)
Extracellular substrate, product concentrations Directly HPLC, GC (3.3)
Cell permeability Indirectly Effect of externally added NAD(P)(H) on reaction rates and yields (3.6.2)
Intracellular substrate, product concentrations Indirectly Effect of additional cell permeabilization on reaction rates and yields (3.6.1)
Whole cell catalyst lifetime under process conditions Directly
Indirectly
Time course analysis of whole cell reductions (3.6.1)
Comparison of whole cell activities and product concentrations (3.6.1)
Total turnover number Indirectly Gram product per gram catalyst (3.6)
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mass transfer limitations over the cell envelope and indicates low
intracellular substrate concentrations. Cell permeability and intracellu-
lar substrate concentration are not directly measurable. Nevertheless,
the effect of externally added NAD(P)(H) on reaction rates (or yields)
gives qualitative information on cell wall integrity. Cell perme-
abilization is characterized by diffusional loss of NAD(P)(H),
i.e. externally added NAD(P)(H) leads to higher reduction rates
and yields. Intact cell membranes are impermeable for NAD(P)H and
no effect is seen upon addition of coenzyme (Rundbäck et al., 2012).
Low conversions that do not increase with added coenzyme indicate
low intracellular (co)substrate concentrations. The combination of cell
permeabilization and externally added coenzyme leads, in these cases,
to higher reaction rates and yields (Table 1).
2.5. Practical use of the decision tree
Fig. 2 pictures the development chain of a bioreduction as a
straight forward process from screening for stereoselective enzymes
to reaction engineering. However, it is frequently more realistic to
see the development process as a circle that might be progressed
through a combination of both forward and backward steps. The
development of a bioreduction is summarized in Table 2 using the
example of o-chloroacetophenone reduction by yeast xylose reduc-
tase. Note that also in the present example the chronical sequence
did not follow the development chain from top to bottom as depicted
in Fig. 2. The starting point was the enzyme CtXR already cloned into
a standard pET vector (pET11a; Häcker et al., 1999) and not the
native C. tenuis strain. The isolated enzyme showed high Prelog-
type stereoselectivity in the reduction of aromatic ketones (Kratzer
and Nidetzky, 2007; Kratzer et al., 2011) (node 3 in Fig. 2 and
Table 2). Especially the reduction of o-chloroacetophenone provided a
potentially interesting route towards (S)-1-(2-chlorophenyl)ethanol,
a chiral key intermediate in the synthesis of a new class of chemo-
therapeutic drugs (Sato et al., 2009). The low stability of the free en-
zyme in the presence of o-chloroacetophenone and (S)-1-(2-Table 2
Development chain of o-chloroacetophenone reduction by CtXR.
# of node/decision rule Object to be examined A
1 Is the microbial host active? Native C. tenuis Y
2 Is the microbial host
stereoselective?
Native C. tenuis Y
3 Is the enzyme stereoselective? Isolated CtXR Y
4 logPsubstrate N 1? o-Chloroacetophenone Y
5 Optical product purity & amount? Product requirement 2
6 Reductase activity ≤ 15 U/mg? CtXR speciﬁc activity Y
M
7 Product concentration ≥100 mM? Yields of aqueous
batch reductions
N
Schlorophenyl)ethanol indicated the application of a whole cell
catalyst (Kratzer et al., 2011) (node 4, logPo-chloroacetophenone 2.2,
https://sciﬁnder.cas.org). The native host was not a practical option
for the required full conversion of 23 g starting material (Eixelsberger
et al., 2013) (node 5, see also node 2) (Fig. 1C). The low speciﬁc
o-chloroacetophenone reductase activity of 4.4 U/mgprotein suggested
the co-expression of CtXR with FDH in an E. coli host (Kratzer et al.,
2011; Mädje et al., 2012) (node 6). The resulting recombinant
whole cell catalyst was used in aqueous batch reductions of
o-chloroacetophenone. Product concentrations of at most 98 mM
indicated the application of isss and ispr to accomplish higher product
concentrations (Kratzer et al., 2011; Schmölzer et al., 2012) (node 7).
3. Methods and applications
3.1. Screening of microbial strains
Screening for NAD(P)H-dependent reductase-activities in microbial
strain libraries has been reported for a wide variety of ketone targets
(e.g. Botes et al., 2002; Homann et al., 2004; Lavandera et al., 2008;
Stampfer et al., 2004; Yasohara et al., 1999). The process of microbe
selection for a speciﬁc reductase-activity is highly empirical, although
a critical evaluation of relevant literature has very often been used to
narrow down the choice of candidate strains (Botes et al., 2002;
Homann et al., 2004; Yasohara et al., 1999). For instance, ﬁnding
solvent-tolerant oxidoreductases was accomplished by screening
microorganisms that are employed as bioremediators and can grow
under extreme conditions (Lavandera et al., 2008). The general screen-
ing approach includes growingof strains according to established proto-
cols and using them, with or without prior cell concentration, for
conversions. Biomass concentrations expressed as gram cell dry weight
per liter (gCDW/L) vary therefore from single digit to low three-digit
values. The upper biomass concentrations used in biotransformations
are generally limited by the viscosity of reaction mixtures to maximally
~200 gCDW/L (Shiloach and Fass, 2005). Addition of easilymetabolizable
compounds to the reaction mixture enables the cell to recycle thenswer Decision
es (370 U/gCDW) (Gruber et al., 2013) Native host contains
stereoselective reductase(s)
es (N99.9% e.e.) (Gruber et al., 2013) Native host is suitable for
product amounts of ~1–5 g
es (N99.9% e.e.) (Kratzer et al., 2011) Keep enzyme
es (logP= 2.2) (https://sciﬁnder.cas.org) Use whole cell reduction
0 g (Eixelsberger et al., 2013) Use recombinant E. coli
es (4.4 U/mg) (Kratzer et al., 2011;
ädje et al., 2012)
Couple to FDH
o (16–98 mM) (Kratzer et al., 2011;
chmölzer et al., 2012)
Use 2nd phase (isss, ispr)
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Homann et al., 2004; 4% in Yasohara et al., 1999), 2-propanol (10% v/v
in Lavandera et al., 2008 and Stampfer et al., 2004) and glycerol
(10% in Botes et al., 2002; 20%Homann et al., 2004) have been previous-
ly reported as co-substrates in screening protocols. The reaction
mixtures are usually buffered to pH-values of 7.0 ± 0.5. The use of
lyophilized cells allows, besides long-term storage of biocatalysts,
improved substrate and product transfer through partially perme-
abilized membranes (Hall et al., 2006; Lavandera et al., 2008;
Stampfer et al., 2004). Culture screens have been accomplished in
micro-centrifuge tubes (Botes et al., 2002; Stampfer et al., 2004), 24
well plates (Homann et al., 2004; Stampfer et al., 2004) or shaken ﬂasks
(Homann et al., 2004). General reaction conditions are 30 °C and
shaking for 8 to 48 h prior to analysis.
3.2. Enzymes from databases
The high abundance of NAD(P)(H)-dependent reductases in nature
(Kaluzna et al., 2004) and the need of industry for chiral alcohols
(Pollard and Woodley, 2007) led to the gathering of reductases and
exploration of their product patterns, enantioselectivities, biochemical
and kinetic data (reviewed in Matsuda et al., 2009). The most
straightforward strategy to ﬁnd a suitable reductase might therefore
start from a search for the required alcohol on SciFinder (database for
references, substances and reactions; http://www.cas.org/products/
sciﬁnder). Amino acids sequence and biochemical characteristics of
enzyme matches can be further found in the BRENDA database
(http://www.brenda-enzymes.org/), gene sequences in PubMed
(http://www.ncbi.nlm.nih.gov/pubmed). Enzymes with similar pro-
tein or DNA sequence can be identiﬁed by an online BLAST search
using the originally match as query (http://blast.ncbi.nlm.nih.gov/
Blast.cgi). In the absence of an enzymematch the search for an alterna-
tive enzyme that produces a structurally closely related alcohol is
suggested. Possible hitsmight catalyze the required reaction as an addi-
tional activity; for instance enzymes from the superfamily of aldo-keto
reductases (https://www.med.upenn.edu/akr/) are well known for
their ability to convert a broad spectrum of ketones (Ni et al., 2011).
Engineering of the enzyme by directed evolution provides a method
to engineer oxidoreductases without the knowledge of structure-
function relationships. Requirement is a suitable screening method to
select large numbers of mutant enzymes. High throughput screening
methods to engineer oxidoreductases with regard to stability, catalytic
activity and substrate speciﬁcity have been previously reviewed
(Johannes et al., 2006). The availability of a structure facilitated engi-
neering of the cofactor preference (Petschacher et al., 2005; Tishkov
and Popov, 2006). Furthermore, ﬁne-tuning of enantioselectivity by
enzyme engineering based on enzyme-substrate docking has been
reported previously (Musa et al., 2009; Zhang et al., 2009). In the rare
case that no reductase is found that catalyzes the target reaction; the
search for a ‘catalophore’ (three-dimensional constellation of functional
groups in the active site) in structural databases might be used for the
identiﬁcation of novel enzymes as recently published by Steinkellner
et al. (2014).
3.3. Analytics
Chiral GCwith standard ﬂame ionization detectors (FID) provide the
required resolution and sensitivity and have been previously used for
sufﬁciently volatile compounds, i.e. up to an analyte boiling point that
is slightly beneath the temperature limit of the chiral column, typically
220–230 °C (Botes et al., 2002; Lavandera et al., 2008; Stampfer et al.,
2004). Chiral HPLC has been used either coupled with refractive
index (RI) detectors for molecules that are UV transparent or with UV
detectors that measure UV absorption of the analytes (Homann et al.,
2004; Schmölzer et al., 2012; Yasohara et al., 1999). Minimal analyte
concentrations that are detectable in GC/FID and HPLC coupled to UVdetectors are in the micromolar range. Detection limits are approxi-
mately one to two orders of magnitude higher when RI detectors are
used. If standardmaterial of alcohols is not available, neither as enantio-
mer nor as racemate, it is oftentimes relatively easy to obtain the
racemate of the target alcohols by chemical reduction of the ketone
substrate using versatile reducing agents such as sodium borohydride
(March, 1992). A comparison of optical rotation to reported chiroptical
data allows determination of the absolute conﬁguration in cases
where standards of alcohol antipodes are missing. The synthesis
of diasteriomeric R- and S-MTPA (α-methoxy-α-(triﬂuoromethyl)-
phenylacetyl) esters is used to determine the absolute conﬁguration of
the product alcohol in rare cases where neither antipode standards
nor chiroptical data are available. The relative proximity of the phenyl
group in the R- and S-MTPA esters to side chains of the alcohol is seen
as chemical shifts of the alcohol side chains in 1H NMR (Dale and
Mosher, 1973).
Strains harboring the desired activity do not necessarily reﬂect
the stereoselectivity of a single enzyme. Reductase-rich organisms
express enzymes with overlapping substrate speciﬁcities and differing
stereoselectivities. A characterization of the enzyme with respect
to speciﬁc activity and stereoselectivity therefore requires isolation of
the protein.
3.4. Reductase activities
Most reductases used in biocatalysis catalyze a hydride transfer from
NAD(P)H to the carbonyl C-atom and a proton transfer to the arising
alcoholate O-atom. Speciﬁc activities are determined by the spectropho-
tometrically measured NAD(P)H consumption in buffered, aqueous
media. Reaction conditions should guarantee substrate concentrations
below inhibitory levels and enzyme stabilities of at least 2min. The sub-
strate solubility in aqueousmedia already dictates the useful concentra-
tion range for initial rate measurements. Concentrations above the
substrate solubility lead to dispersions and destabilize enzymes at the
boundary surface. Furthermore, substrate availability depends on the
amount of dissolved substrate because there is nodirect substrate trans-
fer from a second phase to the biocatalyst (De Bont, 1998). The enzyme
activity measured at the highest dissolvable substrate concentration
equals the maximally obtainable speciﬁc activity. Determination of ini-
tial rates at different substrate concentrations provides information on
substrate inhibition and gives a ﬁrst estimation of enzyme stability.
The amount of puriﬁed protein needed is determined by the enzyme
activity. As a rule of thumb, one unit of enzyme activity measured at a
substrate concentration that allows the exact determination of the
ee-value after reaction is sufﬁcient. Generally, reductases that show spe-
ciﬁc activities below 1 U/mg are less suitable in bioreductions. The en-
zyme stability in the presence of substrates and products in millimolar
concentrations might be very low but can always be increased by the
use of whole cells and addition of a co-solvent from the range of a few
minutes to several hours (Schmölzer et al., 2012). Determination of
the Michaelis-Menten constant (Km), turnover number (kcat) and sub-
strate and product inhibition constants are of immediate importance
when the free enzyme in solution is used as a catalyst. The effective
substrate and product concentrations (i.e. concentrations at the
enzyme) in whole cell reductions differ substantially from bulk concen-
trations and are not easily measurable (Gruber et al., 2013). In these
cases, the catalytic activity at very low substrate concentrations
becomes more important.
3.5. Design of whole cell catalysts based on E. coli
Aside for mass transfer issues, the speciﬁc activity of an E. coliwhole
cell catalyst depends on the speciﬁc activities of the reductase, the
dehydrogenase and the respective expression levels. Finely tuned
co-expression of oxidoreductases is required to optimally exploit the
used enzymes. Recombinant production of the two enzymes in single-
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expression strain. The amount of accumulated recombinant protein is
easily estimated from polyacrylamide gel electrophoresis (PAGE)
(Laemmli, 1970). Functional expression is best checked in initial
rate measurements in the cell-free extract. Additionally, speciﬁc activi-
ties for reductase and dehydrogenase measured in their respective
single-expression strains indicate already the need for up- or down-
regulation in the design of co-expression strains. However, reductase
and dehydrogenase activity ratios obtained from single-expression
strains do not necessarily predict relative expression levels in
co-expression strains. Expression-levels depend on the properties
of the protein itself, but it is not unusual to observe a decline in expres-
sion from single- to co-expression. In principle, co-expression is either
achieved from a duet vector carrying two expression units or from
two different plasmids maintained in one strain.
3.5.1. Duet vectors
Duet vectors provide equal gene dosage of reductase and dehydro-
genase in the producer cell. Novagen (part of Merck4Biosciences)
markets 5 different types of duet vectors. These vectors provide T7
promoters for high-level expression by IPTG induction and require an
E. coli host containing a chromosomal copy of the T7 RNA polymerase
gene (E. coli (DE3)). Duet vectors fromNovagen differ in antibiotic resis-
tance and replicon/copy number i.e. pETDuet-1 vector with ampicillin
resistance and ColE1 replicon/copy number 40; pACYCDuet-1 with
chloramphenicol resistance and P15A replicon/copy number 10–12;
pCDFDuet-1 with streptomycin resistance and CloDF13 replicon/copy
number 20–40; pRSFDuet-1 with kanamycin resistance and RSF1030
replicon/copy number N 100; pCOLADuet-1 with kanamycin resistance
and COLA replicon/copy number 20–40) (Held et al., 2004).These
vectors contain two multiple cloning sites (MCS1, MCS2) with almost
identical upstream transcription and translation signals, i.e. promoter-,
operator-sequences and ribosome binding sites (Held et al., 2003,
2004; Novy et al., 2002). However, duet vectors from Novagen are
lacking a terminator after the MCS1 leading to transcriptional read
through that destabilizes the corresponding mRNA (Sørensen and
Mortensen, 2005). Hence, the gene inserted into the MCS2 is generally
expressed more strongly than the gene cloned into the MCS1. The use
of duet plasmids provides expression of two proteins with only one
antibiotic without plasmid compatibility issues.
3.5.2. Two plasmids
Maintenance of two different plasmids in a single E. coli cell requires
compatible vectors. It is not possible to maintain two plasmids that use
the same mechanism for replication in a single cell. The replication
of one plasmid will be inhibited as a result of an RNA antisense mecha-
nism and one plasmid will prevail while the other will disappear.
Furthermore, plasmid segregation occurs when both plasmids carry
the same antibiotic resistance gene, since antibiotic resistance
needs only one plasmid for maintenance. Therefore, plasmids
sharing origins of replication from the same incompatibility group
or common antibiotic resistance genes should be avoided for
co-expression (Tolia and Joshua-Tor, 2006). The major advantage
of the two-plasmid strategy is a higher ﬂexibility in the combination
of reductases and dehydrogenases. For example, if a reductase is
cloned in a pET-vector with GDH and FDH in pRSF-vectors, enzyme
combinations can be easily changed by re-transformation, thus
avoiding tedious re-cloning.
Generally, co-expression of twoproteins is alsodependent on factors
such as the differences in the relative rate of transcription and
translation, stabilities ofmRNAandprotein, codon usage bias and repeat
structures. Selection of the most suitable expression host is the easiest
way to overcome (some of) these problems. The protease deﬁcient
strain E. coli BL21 is the most widely used host for protein expression.
BL21 (DE3) contains an IPTG inducible T7 RNA polymerase and is de-
signed for the expression of target proteins under T7 promoter control.BL21 star (DE3) is the RNaseE deﬁcient variant that promotes higher
mRNA stability and protein yield. Rosetta and Rosetta 2 are BL21
(DE3) strains that supply tRNAs for rare codons in E. coli. Rosetta strains
are also obtainable as derivatives that provide enhanced disulﬁde bond
formation (Rosetta-gami) (Held et al., 2003). The simplest optimization
strategy is the transformation of plasmids into several BL21 (DE3) de-
rivatives and protein expression at varying induction temperatures.
Co-expression of CtXR and Candida boidinii FDH (CbFDH) has
been previously optimized. These enzymes show speciﬁc activities
of ~4 U/mg under reaction conditions, i.e. 10 mM o-chloroacetophenone
(solubility limit) and 150 to 350 mM sodium formate. Single-expression
of CtXR and CbFDH in E. coli BL21 (DE3) led to 730 U/gCDW and
400 U/gCDW, respectively. Co-expression performed under equal in-
duction conditions resulted in full expression of CtXR but decreased
CbFDH expression to 85 U/gCDW (Kratzer et al., 2011; Mädje et al.,
2012). CbFDH co-expression was investigated with regard to gene
copy number, expression strain and induction temperature. An ex-
perimental set-up following a 23 factorial design was used to evalu-
ate the most relevant variables and possible interactions. All three
main factors signiﬁcantly inﬂuenced CbFDH activity; the effect of in-
teractions were of minor importance. The CbFDH activity increased
3-fold to a level of 250 U/gCDW when a high copy number plasmid,
an expression strain with optimized codon usage and low induction
temperature was used. The CtXR activity was reduced by just 19%
under these conditions. The combined expression of CbFDH and
CtXR in Rosetta 2 (DE3) adds up to 31% of soluble protein in E. coli
(20% CtXR, 11% CbFDH). The obtained percentage is relatively high
considering the codon usage bias of E. coli and yeast. Especially Arg
codons used in CbFDH and CtXR count among the speciﬁcally rare
codons found in E. coli. The Arg codons AGA and AGG are ~10-times
more frequently used in CbFDH and CtXR as compared to its natural
occurrence in E. coli. Furthermore, CbFDH carries a tandem rare Arg
codon double repeat (Arg210, Arg211) (Rare Codon Calculator;
http://nihserver.mbi.ucla.edu/RACC/). Ribosome stalling at the
tandem rare codon double repeat might account for low CbFDH
expression at concurrent high CtXR production. Throttling of CtXR
expression and hence Arg codon consumption led to an increase in
CbFDH co-expression (Mädje et al., 2012).
There is usually no requirement for optimized expression of GDHs
from Bacillus sp. as in most cases the enzyme is coupled to a reductase
with much lower speciﬁc activity. We have previously cloned a Bacil-
lus megaterium glucose dehydrogenase (BmGDH) in a standard
pRSF-1 plasmid (T7/lac operon, kanamycin resistance, RSF origin)
and co-transformed BL21 (DE3) with the pET11a (ampicillin,
pBR322 origin of replication) carrying the CtXR gene. The BmGDH
activity was 2700 U/gCDW, i.e. 10-fold higher as compared to the
CbFDH expression following optimization as previously described.
The obtained amount of functional enzyme corresponded to ~2% of
the soluble protein in E. coli under co-expression conditions (Kratzer
et al., unpublished). Hence, activities of BmGDH and CtXR were bal-
anced in the respective strain without prior expression optimization.
3.5.3. Scale-up of biomass production from shaken ﬂask to bioreactor
Replacement of the shaken ﬂasks by a bioreactor was used to
intensify biomass production. However, this is frequently accompanied
by reduced expression of recombinant protein in E. coli (Choi et al.,
2006). Therefore, the main objective should be to increase the cell
concentration while maintaining high activities of both enzymes
in the co-expression strain. The bioreactor production of the co-
expression strain was optimized in a stepwise manner. First, the biore-
actor cultivation in batch mode was optimized. The complex media in
the shaken ﬂask was replaced by a mineral media that was optimized
with respect to its C/N ratio. The optimal C/N ratio for co-expression
was determined as 4.8 g/g andwas used in all further bioreactor cultiva-
tions. Ampicillin employed in shaken ﬂask cultivations was replaced by
its more stable analogue carbenicillin (Lapidus et al., 1976). Fed-batch
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glucose was nearly depleted, the temperature was reduced to 18 °C,
1 mM of IPTG was added and continuous feeding started (12 h, OD600
25). The nutrient feed was a 15-fold concentrated solution of the
batch media and was fed exponentially. After 41 h an optical density
of 37 and enzyme activities of 650 and 124 U/gCDW were obtained for
CtXR and CbFDH, respectively. Activity per volume was 6-fold higher
for FDH and more than 12-fold higher for CtXR. In this way, biomass
production cost was reduced by 90% compared to previous shaken
ﬂask cultivations (Eixelsberger et al., 2013).
3.6. Reaction
We have previously analyzed bioreductions of o-chloroacetophenone
in terms of gram product obtained per gram cell dry weight.
Productivities (sometimes referred to as biocatalyst yield) speci-
ﬁed as gproduct/gcatalyst reﬂect the product of catalyst activity
(gproduct/(gcatalyst · h)) and effective catalyst lifetime (h). For example,
the half-life of «3 min for the isolated CtXR in the presence of 100 mM
o-chloroacetophenone is far too low for substantial product formation
(Kratzer et al., 2011). In order to harness the enzyme's high
stereoselectivity, native and recombinant whole cell catalysts based
on CtXR were used in bioreductions of o-chloroacetophenone (Gruber
et al., 2013). The comparison is brieﬂy summarized in Table 3.
3.6.1. Comparison of strains
Diagnostic parameters introduced in Table 1 are used to illustrate
differences of native and recombinant whole cell catalysts in the reduc-
tion of o-chloroacetophenone (the comparison is brieﬂy summarized in
Table 3). The required biomass was cultivated under optimal induction
and growth conditions. Recombinant E. coliwas grown in shaken ﬂasks
as previously reported and reached OD600-values of 3 to 3.5 (Kratzer
et al., 2011; Mädje et al., 2012). The native yeast C. tenuis (CBS 4435)
was grown on xylose as the sole carbon source and harvested at an
OD600 of ≤5. Older cultures with OD600-values of N10 or cultures that
grew on glucose showed 90 to 95% lower xylose reductase activities
(Gruber et al., 2013). Intracellular enzyme activities were determined
in the cell-free extracts as described under 3.3. Reductase activities
of ~370 U/gCDW were obtained for C. tenuis cultures, ~50–90% of
the corresponding values for recombinant E. coli strains (Table 3)
(Kratzer et al., 2011; Mädje et al., 2012). E. coli biomass was
re-suspended in potassium phosphate buffer (100 mM, pH 6.5),Table 3
Systematic comparison of native and recombinant hosts based on CtXR in whole cell
reductions of o-chloroacetophenone.
Parameter C. tenuis (Gruber
et al., 2013)
E. coli
Stereoselectivity (ee %) N99.9 S N99.9 S (Kratzer et al., 2011)
Intracellular enzyme activitya
(U/gCDW)
370 420–730 (Kratzer et al.,
2011; Mädje et al., 2012)
Whole cell activityb (U/gCDW) 10 ≤50 (Kratzer et al., 2011)
Activity loss of cell-free extract vs
whole cellc (%)
~97 ~93
Product concentrationd (mM)
Aqueous batch reduction
15 16–65e (Kratzer et al., 2011;
Schmölzer et al., 2012)
Whole cell catalyst lifetimef
(min)
~38 ≥33
4–5 hg (Kratzer et al., 2011)
Maximal total turnover number
(gproduct/gCDW)
0.25 0.39
a Initial rates of 10 mM o-chloroacetophenone reduction in buffer.
b Initial rates of aqueous batch reductions with 100 mM o-chloroacetophenone.
c Comparison of initial rates is admissible despite differing substrate concentrations as
10 mM represents the solubility limit of o-chloroacetophenone.
d Substrate concentration was 100 mM o-chloroacetophenone.
e Results obtained without added NAD+ and without prior cell permeabilization.
f Estimated from whole cell activity and ﬁnal product concentration.
g Taken from time course.supplemented with 150 mM sodium formate (50mM excess as com-
pared to the ketone concentration) (Kratzer et al., 2011; Schmölzer
et al., 2012). Yeast cells were likewise suspended in potassium phos-
phate buffer (50 mM, pH 5.5), supplemented with 200 mM glucose
as co-substrate. Biomass concentrations were adjusted to OD600 of
103 and 115 for E. coli and native yeasts, respectively, equivalent to
approximately 40 gCDW/L (Gruber et al., 2013). Fast deactivation of
the biocatalyst by hydrophobic substrates required substrates to be
added just before mixingwas started (Schmölzer et al., 2012). Gentle
mixing was accomplished on an end-over-end rotator (model SB3
from Stuart, VWR, Austria) at 30 rpm and 25 °C. Analysis of the reac-
tion mixture after 24 h showed that (S)-1-(2-chlorophenyl)ethanol
concentration was 15 mM with an optical purity of ≥99.9% e.e. when
native C. tenuiswas used as catalyst (Gruber et al., 2013). Final product
concentrations of E. coli catalyzed whole cell reductions were between
16 and 65 mM (Table 3) (Kratzer et al., 2011; Schmölzer et al., 2012).
3.6.1.1. Time course analysis. Conversion versus time plots give informa-
tion on initial reduction rates (reductase activity of the whole cell) and
allow estimations of catalyst lifetimes. The linear part of the time course
curve, starting from time point zero, provides the initial rate. Most
accurate and reproducible values are obtained when conversion
between time points are low (10–20%) and at least two measuring
points are in the linear range. Initial rates of 10 and ≤50 U/gCDW were
obtained for C. tenuis and recombinant E. coli, equal to 3 and 7% of
o-chloroacetophenone reductase activities measured in respective
cell-free extracts (Table 3).
The lifetime of the catalyst is the time from reaction start to the time
point when product formation levels off (provided that the conversion
is «100%). Lifetimes of four to ﬁve hours were estimated from time
courses of 100 mM o-chloroacetophenone reduction for recombinant
E. coli (Kratzer et al., 2011). Catalyst lifetimes, as obtained from a
comparison of initial rates and product concentrations are ≥33 min
for E. coli and ~38 min for C. tenuis (Table 3). The example of
o-chloroacetophenone reduction by whole cells based on CtXR
therefore provides an extreme case of catalyst instability. The compari-
son of whole cell catalysts with respect to mass transfer limitations and
catalyst lifetimes suggests higher activity and lower stability of the
E. coliwhole cell catalyst. Fast cell permeabilizationmight cause acceler-
ated enzyme deactivation but also reduced mass transfer over the
membrane leading to the observed low reproducibility of product
concentrations and initial rates (Table 3).
3.6.1.2. Catalyst stability. Incubation of biomass with substrate or prod-
uct under conditions similar to batch reductions and determination
of the remaining activities over time gives precise information on
catalyst deactivation. We have previously incubated recombinant
E. coli in the presence of 0–50 mM o-chloroacetophenone or 1-(2-
chlorophenyl)ethanol (Schmölzer et al., 2012). 100 μL samples
were taken over time and immediately diluted 20-fold with buffer
prior to cell harvesting by centrifugation. Cells were lysed using
B-Per (Bacterial Protein Extraction Reagent from Thermo scientiﬁc)
and subsequently CtXR and CbFDH activities were assayed. Activities
followed an exponential decay over time and half-lives were calculated.
Reference values for CtXR and CbFDH incubated in buffer were
determined to be 5 and 8 days, respectively. At substrate and product
concentrations of 30 mM the half-lives of CtXR and CbFDH decreased
to ≤1%, equal to 1 h. The presence of 50mM 1-(2 chlorophenyl)ethanol
had an especially negative impact on CtXR and CbFDH activities and
decreased the whole cell catalyst half-life to 10 min (Schmölzer et al.,
2012). A higher toxicity of the product, as seen in the bioreduction of
o-chloroacetophenone, renders the application of substrate supply
rather inefﬁcient. In cases of higher substrate toxicity, feeding strategies
have proved successful. Doig et al. (2002) have previously shown that
the lactone substrate bicyclo[3.3.0]hept-2-en-6-one is inhibitory in
whole cell Baeyer–Villiger oxidations at concentrations 10-fold lower
1650 R. Kratzer et al. / Biotechnology Advances 33 (2015) 1641–1652than the products. The inhibitory effect of the lactone substrate was
overcome by substrate feeding and in situ substrate supply.
3.6.2. Reaction optimization
3.6.2.1. pH. Enzymatic carbonyl reduction by NAD(P)H requires proton-
ation of the nascent alcoholate by a proton donor i.e. an acidic amino
acid in the active site. Plots of enzyme activity as a function of pH
show that activities are constant beneath and decrease above a corre-
sponding pKa value. The obtained pKa value most often reﬂects the
pKa value of the proton donor in the active site. Reductase pKa values
are in general between 7 and 8. Dehydrogenases catalyze the reverse
reaction and show activity versus pH proﬁles that mirror the curves
obtained for the reduction reactions. The corresponding pKb values are
again between 7 and 8 (Schlegel et al., 1998). Optimization of the
reaction pH is an additional method to balance reductase and dehydro-
genase activities in cases where the cell is suitably permeabilized.
Schmölzer et al. (2012) have previously optimized the pH of the o-
chloroacetophenone reduction using recombinant E. coli based on the
oxidoreductase couple CtXR and CbFDH. They used 100 mM
potassium phosphate buffer, which was adjusted to pH values of
6.2, 6.5, 7.0, and 7.5 in aqueous batch reductions of 100 mM
o-chloroacetophenone. Yields in aqueous batch reductions of 100 mM
o-chloroacetophenone increased 2-fold upon a pH shift from 7.5 to
6.2. The o-chloroacetophenone reductase activity measured in the
cell-free extract doubled from 347 to 741 U/gCDW in response to a pH
shift from 7.5 to 6.2. The CbFDH activity determined at pH 6.2 decreased
by 25% compared to the value obtained at pH7.5. The reﬂection of CtXR-
activity in reduction yields suggests equal extracellular and intracellular
pH values and hence a high perforation level of the cell. The pH effect
seen on yields of whole cell reductions might be not only due to an
increased reductase activity but also to an increased natural formate
uptake at acidic pH (Lü et al., 2011; Rossmann et al., 1991).
Eixelsberger et al. (2013) reported a pH shift from 6.2 to 7.7 during
the reduction of 300 mM o-chloroacetophenone in 100 mM potassium
phosphate buffer. pH control by automated addition of 1 M H3PO4 in-
creased the conversion from 92.6 to 97.0%.
3.6.2.2. In situ substrate supply and product removal. There are essentially
two strategies for testing different isss and ispr conditions. First, keeping
a constant amount of catalyst per total reaction volume and secondly,
keeping a constant amount of catalyst per aqueous phase volume. The
ﬁrst strategy facilitates comparison of various conditions based on
total reaction volume whereas the second strategy might provide a
more knowledge-based optimization procedure by keeping aqueous
phase conditions constant. Both optimization strategies are simpliﬁed
by preliminary assessment of substrate and product toxicity towards
the whole cell catalyst (see section Catalyst stability under 3.6.1.2)
separately frommeasurement of distribution coefﬁcients in the absence
of biomass.
Further optimization of the o-chloroacetophenone reduction by
recombinant E. coli was started with the selection of suitable second
phases. Kratzer et al. (2008, 2011) have previously shown that relatively
polar organic solvents with log P b 4 are not well suited as second
phases in E. coli based reductions. Therefore the common solvents
hexane, heptane and dodecane covering a log P from 4.11 to 6.8 and
the ionic liquid BMIMPF6 were selected. The substrate was pre-
dissolved in the various solvents. Reactions were started by addition
of E. coli cells suspended in buffered co-substrate solution. Overall
concentrations of cells were 40 gCDW/L, substrate concentrations
100 or 200 mM and co-substrate concentrations exceeded substrate
concentrations by 50 mM. Parallel experiments containing additionally
either 0.5 mM NAD+, 36 μM polymyxin B sulfate or both were also
made. The addition of NAD+ led to higher product yields when no
co-solvent, hexane or heptane was used. No effect was seen when
NAD+ was added to reaction mixtures containing dodecane or ionicliquid. Improved yields by the addition of NAD+ suggest either solvent
or substrate permeabilization of the cell wall (Table 1). Controlled
permeabilization with polymyxin B sulfate led to further yield
improvements in reaction mixtures without co-solvent, with hexane
or heptane. The absence of yield improvement by polymyxin B sulfate
when dodecane or BMIMPF6 were used as second phases suggests
that the substrate concentrations in the aqueous phase were too low
(Table 1).The combination of externally added hexane, NAD+ and
polymyxin B sulfate as well as a pH shift from 7.5 to 6.2 led to an
almost 20-fold improved product concentration, compared to the
standard, aqueous batch reduction. The conversion of 300 mM
o-chloroacetophenone using 50 gCDW/L was scaled-up to 500 mL.
Hexane (20% v/v) served as second phase during the reaction and was
also used in subsequent product extraction. Reaction and product
isolation were performed in a 1 L bioreactor using stirrer, pH and
thermostatic control. The product (S)-1-(2-chlorophenyl)ethanol was
isolated in a total yield of 86%(Fig. 1C) (Eixelsberger et al., 2013).
3.7. Scale-up of whole cell bioreductions
Each of the unit operations: cell production, bioreduction and prod-
uct recovery constitutes a scale-up task with particular requirements.
Cultivation of recombinant E. coli is generally benchmarked by the ob-
tained recombinant protein per liter of growth medium (Schmid et al.,
2001). High enzyme titers of up to 10 g/L were previously obtained
from high cell density cultures (reviewed in Choi et al., 2006). One of
themain problems in the scale-up of E. coli cultivation is acetate forma-
tion due to (locally) high glucose concentrations and oxygen transfer
limitations. E. coli produces acetate as an extracellular co-product of
the glucose overﬂow metabolism and, under anaerobic conditions, the
mixed-acid fermentation. Acetate decelerates growth even at concen-
trations as low as 0.5 g/L, and it inhibits protein formation (Xu et al.,
1999). Cell concentrations of up to 100 gCDW/L require hence bioreactors
with high mixing efﬁciency, aeration with oxygen enriched air or pure
oxygen, suitable nutrient feeding strategies and, furthermore, efﬁcient
cooling (Choi et al., 2006). The kLa value as a measure of gas–liquid
distribution and mixing efﬁciency provides a useful scale-up criterion
for E. coli cultivation. Optimized culture conditions obtained from
microwell plates have previously shown to translate into 7.5 L and
75 L stirred tank reactors when kLa values were kept constant. Cell
growth, protein expression and substrate consumption were accurately
translated (Islam et al., 2008). Nutrient feedingwith feedback control is
widely employed for the high cell density cultivation of E. coli. pH value
and oxygen concentration increase when the glucose becomes deplet-
ed. Controlling pH or dissolved oxygen and keeping it constant by feed-
ing concentrated nutrient solution into the bioreactor provides a
glucose concentration that is near zero. Overfeeding with glucose and
concomitant acetic acid formation is thereby prevented. Process param-
eters like speciﬁc growth rates (pre- and post-induction), induction
times and inducer concentrations individually affect expression of
reductase and dehydrogenase in co-expression strains (Choi et al.,
2006). The requirement for high and balanced expression of both activ-
ities represents an additional scale-up criterion in the biomass produc-
tion (Mädje et al., 2012; Eixelsberger et al., 2013). Use of a high
catalyst loading that is sufﬁcient inexpensive (67 €/kg at 10 m3 cultiva-
tion volume, Tufvesson et al., 2011) might compensate for low cell ac-
tivities but will hamper product isolation. A maximal catalyst loading
of 50 gCDW/L was previously published for two liquid phase, whole cell
bioreductions in order to limit product loss in downstream processing
to ≤20% (Eixelsberger et al., 2013). The bioreduction was performed in
a stirred tank reactor at 500 mL scale. Liquid–liquid dispersion was
performed with a Rushton turbine at a stirrer speed of 500 rpm and a
power input per unit volume of 1.19 W/dm3. The maintenance of con-
stant interfacial area per unit volume was identiﬁed as key parameter
for the scale-up of two liquid phase, whole cell biotransformations
(3 to 75 L; Cull et al., 2002). Constant power input per unit volume
1651R. Kratzer et al. / Biotechnology Advances 33 (2015) 1641–1652was found to be the most suitable scale-up parameter. A minimal value
of 0.38 W/dm3 was published for the scale-up of two liquid phase,
whole cell biotransformations applicable to reactors with three-stage
Rushton impeller system (Cull et al., 2002). However, a low catalyst
concentration of ~3.5 gCDW/L, as used by the authors, might not be com-
parable to reaction mixtures with high catalyst loading. The formation
of a (kinetically) stable emulsion when a catalyst concentration of
50 gCDW/L was used, as reported by Eixelsberger et al. (2013), might re-
quire further scale-up criteria. Though, the performance of a batch
bioreduction in a standard bioreactor for the cultivation of bacteria or
yeast will always be possible. The efﬁciency of product isolation in
whole cell biocatalysis strongly relates to phase separation quality.
Product separation from the biomass in large scale bioreduction/
biooxidation mixtures include ispr onto beads (Vicenzi et al., 1997), liq-
uid extraction of the product following the bioreduction (Baldwin et al.,
2008), separation of the biomass from the product ﬂow by amembrane
and in situ product crystallization and product crystallization subse-
quent to the bioreduction (Buque-Taboada et al., 2006).
3.7.1. Product isolation
Product extraction from reaction mixtures containing whole cells
has been previously described as ‘downstream nightmares’ (Chen,
2007). Vicenzi et al. (1997) reported on a 300-L scale bioreduction of
3,4-methylene-dioxyphenyl acetone to the corresponding S-alcohol by
Zygosaccharomyces rouxii. Substrate was in situ supplied on a hydropho-
bic resin with 500 μm particle size and the product likewise extracted
from the aqueous phase onto the resin. A reactor (350 L) containing a
ﬁlter on a shaft (33 rpm, pore size 100–200 μm) was used for the
bioreduction and product isolation. Filter agitation provided a ﬂuidized
bed of resin and yeast cells with low-shear mixing during the reaction.
Subsequent ﬁltering retains beads on the screen and removes biomass;
constant revolving of the screen impedes ﬁlter clogging by the biomass.
The product was recovered in a yield of 85 to 90% by washing the resin
with acetone. For a higher yield the diluted, aqueous phase containing
the remaining product was passed through a bed of resin. Spontaneous
phase separation of a Baeyer–Villiger oxidation at 200-L scale using a
whole cell biocatalyst at an exceptionally low catalyst concentration of
1.5 gCDW/L is emphasized. The biotransformation was performed in
aqueous medium with subsequent product extraction using 20% v/v
ethylacetate. Spontaneous separation was accelerated by the addition
of 15% w/v sodium chloride (Baldwin et al., 2008). Buque-Taboada
et al. (2006) reviewed the removal of chiral alcohols from biotrans-
formation by crystallization at industrial scale. The reduction of
4-oxoisophorone to levidione at 1.65 m3 was used as a base case by
the authors. The reduction was performed in a stirred tank reactor
coupled with an external crystallizer separated by an ultraﬁltration
membrane for cell retention. Crystallization was also used for the
isolation of the product (R)-N-(2-hydroxy-2-pyridin-3-yl-ethyl)-2-
(4-nitro-phenyl)-acetamide (100 g/L) from a large-scale whole cell
bioreduction mixture. Downstream processing included dissolution
of the precipitated alcohol by acidiﬁcation, ﬁltration of the catalyst
Candida sorbophila and addition of base to crystallize the alcohol
(Moore et al., 2007). Product isolation constituted amajor cost factor
in these examples and additional separation of unreacted starting
material would further increase downstream processing cost. In
particular at larger scale catalyst loading has to be optimized with
respect to both conversion as well as product separation.
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